Table 4.
Outcome, RSV Genomic Load Quartilea | Unadjusted Modelb |
Adjusted Modelc |
||
---|---|---|---|---|
OR (95% CI) | P Value | OR (95% CI) | P Value | |
LOS ≥3 d | ||||
1 | Reference | … | Reference | … |
2 | 1.29 (.93–1.78) | .13 | 1.26 (.92–1.74) | .15 |
3 | 1.65 (1.35–2.00) | <.001 | 1.65 (1.33–2.04) | <.001 |
4 | 1.69 (1.31–2.19) | <.001 | 1.73 (1.29–2.32) | <.001 |
Intensive care use | ||||
1 | Reference | … | Reference | … |
2 | 1.09 (.77–1.53) | .64 | 1.07 (.77–1.48) | .69 |
3 | 1.15 (.78–1.70) | .49 | 1.07 (.70–1.64) | .76 |
4 | 1.60 (1.11–2.31) | .01 | 1.51 (1.00–2.28) | .048 |
Abbreviations: CI, confidence interval; LOS, length of hospital stay; OR, odds ratio.
a Threshold cycle quartiles for RSV genomic loads were defined as follows: 1 (lowest quartile), ≥25.9; 2, 22.5–25.8; 3, 20.2–22.4; and 4 (highest quartile), <20.2.
b Unadjusted model controlling for clustering of patients within the sites, using the generalized estimating equations.
c Multivariable model controlling for 10 patient-level variables (age, sex, race/ethnicity, gestational age, maternal smoking during pregnancy, history of wheezing, history of eczema, comorbid medical disorder, duration of difficulty breathing before hospitalization, and viral coinfection status [RSV plus rhinovirus and RSV plus nonrhinovirus pathogens]) and clustering of patients within the sites.